🔥 42 IAS Prelims 2026 Questions Themes Came Directly from Our Expected Topics. Click for the Proof. 🔥 Free IAS Guidance Programme. Click Now. 🔥 Free Mains Performance Enhancement Programme For IAS Mains 2026. Click Now. 🔥 Free Ethics & Essay Marks Improvement Programme For IAS Mains 2026. Click Now.

What is the Central Drugs Standard Control Organisation (CDSCO)?

What is the Central Drugs Standard Control Organisation (CDSCO)?

Important for UPSC Prelims: Governance | Health

About CDSCO

  • The Central Drugs Standard Control Organisation (CDSCO) is India’s National Regulatory Authority (NRA) for drugs, medical devices, and cosmetics.
  • It functions under the Drugs and Cosmetics Act, 1940.
  • It regulates the approval, import, manufacture, sale, and distribution of drugs and notified medical devices.
  • It ensures that medicines available in India are safe, effective, and of standard quality.

Administrative Setup

  • Nodal Ministry: Ministry of Health & Family Welfare
  • Administrative Control: Directorate General of Health Services (DGHS)
  • Headed by: Drugs Controller General of India (DCGI)
  • Headquarters: New Delhi

Major Functions of CDSCO

  • Approves new drugs before marketing in India.
  • Grants permission for clinical trials.
  • Prescribes standards for drugs and medical devices.
  • Regulates the quality of imported drugs.
  • Coordinates the activities of State Drug Control Organisations.
  • Conducts post-market surveillance and orders drug recalls when required.

Licensing Responsibilities

  • CDSCO: Approval of new drugs, clinical trials, import licences, and regulation of certain specialised drugs.
  • State Drug Control Authorities: Licensing of manufacture, sale, and distribution of most drugs.
  • Joint Responsibility: Licensing of blood and blood products, vaccines, sera, and IV fluids.

Conclusion

  • CDSCO is the cornerstone of India’s drug regulatory system, ensuring that medicines reaching the public are safe and of standard quality.
This concept has been mentioned in the following article:

LAG-3-based Dual Immunotherapy (RELOPDUO): A New Approach in Cancer Treatment  
×

FREE IAS GUIDANCE PROGRAMME

Enroll Now